Key result
Imidapril outperforms tested ACE inhibitors in preventing pressure-induced cardiac hypertrophy in rats.
Why the study?
The comparative suppressive effects of different ACE inhibitors on pressure-induced cardiac hypertrophy in aortic-banded rats were unclear.
Do different ACE inhibitors (imidapril, enalapril, quinapril) have varying efficacies in preventing pressure-induced cardiac hypertrophy in aortic-banded rats?
Do different ACE inhibitors (imidapril, enalapril, quinapril) have varying efficacies in preventing pressure-induced cardiac hypertrophy in aortic-banded rats?
Answers are grounded in this paper and cite their sources.
Imidapril is more potent than enalapril and quinapril in preventing pressure-induced cardiac hypertrophy in a rat model, likely due to its combined effects on cardiac ACE activity and left ventricular end diastolic pressure.
Imidapril, enalapril and quinapril were subcutaneously administered to aortic-banded rats by osmotic minipumps to compare the suppressive actions of these angiotensin converting enzyme (ACE) inhibitors on pressure-induced cardiac hypertrophy. Among the three drugs tested, imidapril was most potent for the prevention of cardiac hypertrophy, although equipotent hypotensive doses were used. Imidapril reduced both serum and cardiac ACE activities, while enalapril reduced only the former. Quinapril also reduced both, however, it was less potent at reducing the former compared to imidapril. Moreover, only imidapril significantly decreased left ventricular end diastolic pressure, which tended to be increased by aortic-banding. The lipophilicity of ACE inhibitors could not explain the more potent suppressive action of imidapril on cardiac hypertrophy because the lipophilicity of imidaprilat, an active metabolite of imidapril, was as low as an active metabolite of enalapril; i.e., much lower than an active metabolite of quinapril. The efficacy of ACE inhibitors on pressure-induced cardiac hypertrophy depends not only on an inhibitory effect on cardiac ACE activity, but also on other actions such as their effect on left ventricular end diastolic pressure.
No takes yet. Share an insight, caveat, or question.
Kurosawa et al. (1999) studied Pressure-induced cardiac hypertrophy. Imidapril, enalapril, and quinapril vs. Each other was evaluated on Suppression of pressure-induced cardiac hypertrophy. Imidapril was the most potent of the tested ACE inhibitors for preventing pressure-induced cardiac hypertrophy in aortic-banded rats, reducing both serum and cardiac ACE activities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: